2015 Debates and Didactics in Hematology and Oncology Conference
Indolent Lymphoma: A More Complex Malignancy Than Once Thought
With a growing number of options for follicular lymphoma, clinicians may wonder whether there is one best regimen. James O. Armitage, MD, FACP, FRCP, Professor of Medicine at the University of Nebrask...
Positioning Targeted and Immunotherapy-Based Approaches in Lung Cancer
With immunotherapy changing the face of lung cancer, is there still a place for targeted therapy? Two experts from Emory University debated this issue at the 2015 Debates and Didactics in Hematology a...
HPV-Positive Head and Neck Cancer: When Can Chemotherapy Be Omitted?
Are there patients with locally advanced squamous cell carcinoma of the head and neck associated with human papillomavirus (HPV) for whom chemotherapy can be omitted? Experts debated this question at ...
Mantle Cell Lymphoma: Is Transplantation Still Necessary?
Autologous stem cell transplantation has played a critical role in the treatment of mantle cell lymphoma, but in the age of novel treatments, is it always warranted? Two experts in the field explored ...
Double-Hit Lymphoma: Many Treatment Strategies, No Standard of Care
"Double-hit lymphoma” represents a challenging malignancy without a standard-of-care treatment, although outcomes for some patients are better than was once believed, according to Jonathon B. Cohen, ...
Eileen M. O’Reilly, MD, on Hepatobiliary Cancer: Multimodality Approaches
Jeffrey S. Weber, MD, PhD, on Discontinuing Immunotherapy: When Is the Right Time?
Kathrine Rugbjerg, PhD, on Adolescents and Young Adult Survivors: Late Effects
Johan F. Vansteenkiste, MD, PhD, on NSCLC: Immunotherapy and Targeted Treatments
David Palma, MD, PhD, on Oligometastatic Tumors: Results From the SABR-COMET Trial
